Atopic Dermatitis
Conditions
Keywords
Atopic dermatitis, Oral roflumilast, Moderate-to-severe AD, Efficacy, Safety, Adolescents and Adults
Brief summary
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in patients aged 12 years and older with moderate-to-severe atopic dermatitis All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in SCORAD (Scoring Atopic Dermatitis) score from baseline to Week 12. Secondary outcome include safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups to explore potential differences in response or safety.
Interventions
DRUGOral roflumilast
Participants will receive oral roflumilast. The initial dose is 250 mcg once daily for the first 10 days, followed by a dose escalation to 500 mcg once daily for the remainder of the 12-week treatment period. Route: Oral Schedule: Daily for 12 weeks Duration: 12 weeks
Sponsors
Mansoura University Hospital
Nora Mohamed Abdelrazik
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an open-label study: neither the participants nor the investigators are blinded. All participants receive oral roflumilast, and both participants and study staff are aware of the treatment assignment. No placebo or comparator is used.
Intervention model description
This is a single-arm, open-label pilot study in which all participants, both male and female, receive oral roflumilast. Participants will not be randomized to different treatments. Male and female participants will be analyzed as subgroups to explore potential sex-based differences in safety and efficacy. No placebo or comparator group is included.
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* AD patients ≥ 12 years in whom systemic therapy is indicated. * Patients who don't use other systemic therapy for AD in the last 2 months (or naïve who didn't use any systemic therapy before). * Safe contraception during the study.
Exclusion criteria
* Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception. * Age \<12 years. * Other concomitant AD systemic treatments such as cyclosporins and biologics. * Previous systemic treatment of AD in the last 2 months. * Patients receiving inducers or inhibitors of cytochromes CYP3A4 and CYP1A. * Other systemic diseases other than COPD, especially hepatic impairment. * Hypersensitivity to the active substance of roflumilast or to any of its excipients. * The use of contraception with gestodene and ethinylestradiol. * Unreliable patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome of the study is the change in the SCORAD Index from baseline to the end of treatment | Baseline and Weeks 4, 8, and 12. | SCORAD is a validated scoring system that provides a comprehensive assessment of atopic dermatitis by combining: Extent of eczema: The percentage of total body surface area affected (0-100%), assessed using standard dermatologic mapping. Intensity of clinical signs: Six features-erythema, swelling ,oozing/crusts, scratch marks, lichenification, and dryness-each graded from 0 (absent) to 3 (severe). Patient-reported symptoms: Daily pruritus (itch) and sleep disturbance, each rated on a 0-10 visual analogue scale. The total SCORAD score ranges from 0 to 103, with higher values indicating more severe disease. Changes in SCORAD are reported as: Absolute reduction, and Percentage improvement from baseline (e.g., SCORAD-50 or SCORAD-75). This outcome measure captures both objective clinical improvement and patient-experienced symptom relief, providing a holistic evaluation of treatment efficacy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety - incidence of treatment-emergent adverse events and laboratory abnormalities. | Throughout treatment; labs at baseline and monthly (Weeks 4, 8, 12). | Incidence and severity of adverse events (including diarrhea, nausea, abdominal pain, weight loss, decreased appetite, insomnia, headache) and clinically significant changes in CBC, hepatic profile, and serum creatinine. |
Countries
Egypt
Contacts
Primary ContactNora Mohamed Abdelrazik, MD Dermatology
Backup ContactAhmed Ibrahim Ali, Master degree of Dermatology
Outcome results
None listed